We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App




Immunobiomarkers in Chronic Rhinosinusitis Correlate with Clinical Severity

By LabMedica International staff writers
Posted on 06 Jul 2022

Chronic rhinosinusitis comprises a heterogeneous group of inflammatory disorders. More...

It is assumed that the disease process lasts over 12 weeks and is accompanied by two or more symptoms, such as nasal discharge/postnasal drip, nasal congestion, sinus pain/pressure, and anosmia/hyposmia.

Chronic rhinosinusitis (CRS) is characterized by epithelial inflammation and tissue eosinophilic infiltration. Interleukin-5 (IL-5), periostin (POSTN), and IL-33 are important factors that act as chemoattractants for eosinophils, and a tissue-remodeling protein positively correlated with eosinophils in blood and mediators of eosinophilic infiltration.

Clinical Scientists at the Medical University of Lodz (Lodz, Poland) carried out carried out a study in a cohort of 93 Caucasian patients, aged between 22 and 65 years: group I eosinophilic CRS without nasal polyps (CRSsNP) included 53 patients, 13 of whom were diagnosed with allergy; group II eosinophilic CRS with nasal polyps (CRSwNP) included 40 patients, 16 of whom were diagnosed with allergy. In each case, allergy was confirmed by skin prick testing. The reference group was composed of 40 patients with nasal septum deviation (NSD).

Tissue samples were collected during the planned endoscopic procedures. These comprised sinonasal mucosal and polyp tissue from CRS patients, or a fragment of the mucosa of the lower nasal concha from NSD patients. Blood samples were used to evaluate serum IL-5, periostin and IL-33 levels using ELISAs (Thermo Fisher Scientific, Waltham, MA, USA). Tissue samples, after processing, were examined with an Olympus light microscope (Olympus, Tokyo, Japan). The epithelial infiltration with eosinophils were evaluated. Determinations of total IgE levels were performed by an immunoenzymatic method on a UNI-CAP immunoanalyzer (Phadia, Uppsala, Sweden). The expression of IL-5, POSTN and IL-33 mRNA was determined in sinonasal mucosal samples and in nasal polyp tissue by real-time PCR.

The investigators reported that comparison between non-allergic and allergic patients with and without NP show significant differences for total IgE serum levels. NP tissue demonstrated significantly higher IL-5 and POSTN mRNA expression than the sinonasal tissue in the CRSsNP and CRSwNP groups. CRS groups demonstrated elevated IL-33 mRNA expression in comparison to controls irrespective of the presence of NP. No correlation was found between IL-5, POSTN and IL-33 mRNA expression and disease severity. CRSwNP group demonstrated significantly higher serum IL-5, POSTN and IL-33 protein levels than controls, and this corresponds to disease severity.

The authors concluded that serum IL-5, POSTN and IL-33 levels may be useful for identifying CRSwNP patients and predicting the disease severity. Clinical phenotyping of patients with CRS based on selected inflammatory markers could enhance the early recognition of sinus disease, thus representing a promising new therapeutic approach. The study was published on June 25, 2022 in the journal BMC Immunology.

Related Links:
Medical University of Lodz 
Thermo Fisher Scientific
Olympus 
Pharmacia 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.